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Abstract 
Objective: To determine the prothrombin time and activated partial thromboplatin time among type 2 none insulin dependent 
Diabetes Mellitus Patients. 
Materials and methods  
Descriptive, prospective analytical case-control based study conducted in Abdelrahamn Elsedari Hospital, Sakaka city, Aljouf 
Region, Saudia Arabia during the period of March to July 2009. Fifty patients and ten normal controls were studied. Patients were 
those who fulfilled the clinical diagnosis of type II none insulin dependent Diabetes Mellitus of either sex in all age groups, on or off 
treatment. The controls were normal, non- Diabetes Mellitus individuals of either sex. 
Results 
The results Show that the mean level of prothrombin time type 2 diabetic patients was 12.0 Sec and of control was 11.1 Sec, it was 
significantly correlated (P value = 0.02) and the mean level activated partial thromboplastin time  (APTT) was 30.7 Sec and of 
control was 31.2 Sec. This result was none significant (P. value = 0.826). 
Conclusion 
Our data further demonstrated that patients with type 2 diabetes mellitus had hypercoagulable state and hypofibrinolysis thereby 
indicating that the activation of coagulation and reduced fibrinolytic activity may contribute to the increased risk of vascular disease 
in type 2 diabetic patients. 
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Introduction 
  Abdominal (android) obesity was first proposed to 
be a risk factor for the development of atherosclerosis 
and type 2 diabetes mellitus (T2DM) over 40 years ago[1]. 
Metabolic alterations accompanying the visceral 
distribution of fat lead to arterial hypertension, 
dyslipidemia, insulin resistance and subsequently to 
T2DM[2]. This phenomenon is associated not only with 
classical atherosclerotic risk factors but also with 
coagulation and fibrinolysis abnormalities[3]. 
Hypercoagulation in abdominal obesity is thought to be 
caused primarily by the synthesis of factors activating 
coagulation and inhibiting fibrinolysis (for example factor 
VII activator and the fibrinolytic inhibitor PAI-1) in adipose 
tissue [4]. Hemostatic abnormalities may also result from 
the synthesis in adipose tissue of cytokines that are 
mediators of inflammation and insulin resistance, such as 
interleukin 6 and TNF-alpha[5].   In addition to this direct 
effect, the metabolic and lipid alterations that accompany 
obesity and T2DM are likely to indirectly influence 
coagulation properties in these patients. Other factors 
that may be implicated in the generation of 
hypercoagulation state in visceral obesity and T2DM are 
endothelial injury and dysfunction[4]. The purpose of the 
present study was the assessment of the relationship of 
some hemostatic factors (PT and APTT) in patients with 
T2DM. 
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Materials and methods  
This is a descriptive, prospective analytical case-
control based study conducted in Abdelrahamn Elsedari 
Hospital, Sakaka city, Aljouf Region, Saudia Arabia 
during the period of March to July 2009 to determine the 
prothrombin time and activated partial thromboplatin time 
among type II none insulin dependent Diabetes Mellitus 
Patients. 
Fifty patients and ten normal controls were studied. 
Patients were those who fulfilled the clinical diagnosis of 
type II none insulin dependent Diabetes Mellitus of either 
sex in all age groups, on or off treatment. The controls 
were normal, non- Diabetes Mellitus individuals of either 
sex.  
Exclusion criteria:  patients (male and female) with 
previous history of venous or arterial thrombosis and 
hypertensive patients, who received antiplatelet or 
anticoagulant drugs in the previous 15 days, were 
excluded from the study. 
Consent was obtained from the selected individuals 
after being informed them with all detailed objectives of 
the study, blood samples were collected from both 
patients and controls and proceed to platelet poor citrate 
plasma (PPP) preparation [6]. Prothrombin time (PT) and 
Activated partial thromboplastin time (APTT) were 
determined using Coagulometer model, Fibron I, Vitallab, 
The Netherlands. Data from study groups were analyzed 
by computer using SPSS(statistical Package for Social 
Science), to measure the mean and standard deviation, 
p.value of < 0.05 was regarded as statistically significant. 
 
Results and Discussion 
Enhanced activation of the clotting system has been 
previously reported in patients with type 1 or type 2 
diabetes [7]. This activation of blood coagulation has 
recently been implicated as an important contributing 
factor for the occurrence of vascular complications in 
diabetes [8]. In large epidemiological studies, the 
procoagulant factors (fibrinogen and factor VII) have 
been described as independent predictors of 
cardiovascular events in diabetic and nondiabetic 
subjects. Our finding indicated a significant correlation 
between type 2 none insulin dependent Diabetes Mellitus 
and family history (Table 1), while the duration of 
diabetes between 1 month up to 5 years was highly 
incidence among the study group which was explained 
the increased of  diabetes in recent years (Fig. 1). 
The pathogenetic mechanism of the clotting 
activation in diabetes is not completely clear. 
Perturbance of components of the anticoagulant system 
associated with hyperglycemia may play an important 
role as exemplified in hyperglycemia inducing depressed 
biological activity of the anticoagulant protein AT-III in 
diabetic and nondiabetic subjects[9]. Structural 
modification due to no enzymatic glycation was 
suggested as the causative factor of this AT-III 
dysfunction[10]. In various studies, it was reported that 
plasma levels of AT-III were decreased[11] or 
unchanged[12].  
Abnormalities of the extrinsic pathway may also 
cause hypercoagulability in diabetic patients. The mean 
plasma PT level was found to be either decreased or 
increased in various reports depending on the type of 
diabetes (Table 2). While reduced plasma levels APTT 
have been described in type 1 diabetic patients, they 
were found to be elevated in those with type 2 diabetes[8]. 
The Extrinsic or intrinsic pathways did not change in our 
diabetic patients. Hyperglycemia has been considered to 
be the causative factor of the abnormalities of the 
anticoagulant pathway. In our type 2 diabetic patients, we 
found a significant (p= 0.02) correlation between mean 
PT patients compared to control groups. Increased levels 
of PT in subjects with type 2 diabetes are associated with 
macrovascular mortality[13]. Several studies have shown 
that levels of PT are increased in both type 1 and type 2 
diabetic patients[12] and that glycemic control normalizes 
PT levels in diabetic patients[14]. In our study, we found 
an increased PT in type 2 diabetics in comparison with 
the healthy controls. However, the mean values of both 
groups were within normal ranges of our laboratory. PT 
did not differ between the diabetic patients with and 
without vascular complications. Previous studies of the 
fibrinolytic system in diabetes have provided conflicting 
results; type 2 diabetes is often associated with profound 
depression of fibrinolysis[15], while Aso et al, 2000[16] 
reported that both coagulation and fibrinolysis are 
enhanced concomitantly in patients with type 2 diabetes 
mellitus. Our findings of increased plasma levels of PT 
and decreased APTT (but not significant) are consistent 
with abnormal coagulation mechanism and may be 
interpreted as a tendency to thrombosis with 
cardiovascular disease for diabetic patients. 
 
Table 1 Family history of T2DM among patients (n, 69) and 
controls (n, 10). 
 
 
 
 
 
 
 
 
P.Value statistical significant < 0.05 
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Table 2 The mean level of prothrombin time (PT) and activated 
partial thromboplastin time (APTT) in T2DM patients (n, 69) and 
control (n, 10). 
 
 
 
 
 
 
P.Value statistical significant < 0.05 
NS: None Statistical significant 
 
Fig. 1 The duration of T2DM in the study group (n, 69) 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
Our data further demonstrated that patients with type 
2 diabetes mellitus had hypercoagulable state and 
hypofibrinolysis thereby indicating that the activation of 
coagulation and reduced fibrinolytic activity may 
contribute to the increased risk of vascular disease in 
type 2 diabetic patients. Our study, patients with T2DM 
showed independent factors determining hyper-
coagulation which suggested including metabolic control, 
lipids and haemostatic disorders for subjects with 
diabetes at risk of developing vascular complications. 
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